FDA Drug Recall Alert – DOXOrubicin Hydrochloride Liposome Injection 50mg/25 mL
| Date: | May 27, 2026 |
| From: | Health Plan of San Joaquin/Mountain Valley Health Plan (“Health Plan”) |
| To: | Health Plan Practitioners, Facilities, and Hospitals |
| Type: | Informational/Educational |
| Subject: | FDA Drug Recall Alert – DOXOrubicin Hydrochloride Liposome Injection 50mg/25 mL |
| Business: | Medi-Cal Managed Care/Medicare Dual Special Needs Program (D-SNP) |
On May 13, 2026, the Food and Drug Administration (FDA) released a recall announcement on DOXOrubicin Hydrochloride Liposome Injection 50mg/25 mL.
This is for informational purposes only. You may or may not have administered the medication. Please disregard if you have not been affected by this recall.
For the complete details regarding this recall announcement, please visit the following web link: https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/sun-pharmaceutical-industries-inc-sun-pharma-initiates-voluntary-us-nationwide-recall-doxorubicin?utm_medium=email&utm_source=govdelivery
Sun Pharmaceutical Industries, Inc. (Sun Pharma) Initiates Voluntary U.S. Nationwide Recall of DOXOrubicin Hydrochloride Liposome Injection 50mg/25 mL Due To Potential Presence of Glass Particles
Company Announcement
Sun Pharma is voluntarily recalling within the U.S. to the hospital/user level, one batch of DOXOrubicin Hydrochloride Liposome Injection 50mg/25 mL, Lot # HAG2581B, Expiration 05/2027 (675 vials). The single batch of 675 vials is being recalled due to the detection of glass particles in some vials during production.
Affected Product
The affected DOXOrubicin Hydrochloride Liposome Injection batch is Batch HAG2581B, Expiration 05/31/2027. The product can be identified by the label (Aisling Label), each vial is labeled to indicate the name of the product: DOXOrubicin Hydrochloride Liposome Injection 50mg/25 mL, NDC 72603-200-01 Lot# HAG2581B, Expiration 05/31/2027.
What to Do
Distributors/retailers/hospitals/users that have the product should stop using and return to place of purchase or discard the product. Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using this drug product. To report suspected adverse events, contact NorthStar Rx LLC at 1-800-206-782.
Contact Information
Customers with questions regarding this recall can contact Inmar Inc., (Sun Pharma’s recall processor) by 855-745-9357, Monday through Friday between 8:30 am and 5:00 pm, U.S. Eastern Time, or via rxrecalls@inmar.com.
Inmar, Inc.
3845 Grand Lakes Way
Grand Prairie, TX 75050
Tel. 855-745-9357
Fax. 817-868-5362
Email: rxrecalls@inmar.com
If you have any further questions, please contact your Provider Services Representative, or call our Customer Service Department at 1-888-936-PLAN (7526). You may also visit https://www.hpsj.com/alerts/ for online access to the documents shared. The most recent information about Health Plan and our services is always available on our website www.hpsj-mvhp.org
